ICARIA-MM: SARCLISA + Pd

Subgroup Data for SARCLISA + Pd

Consistent PFS results were seen across subgroups with SARCLISA + Pd1,2

  Favors Favors No. of events/total  
Subgroup SARCLISA + Pd Pd SARCLISA + Pd Pd HR (95% CI)
All patients
A forest plot composed of dots within bracketed lines represents the hazard ratio and confidence intervals, respectively, of the
PFS results for each patient subgroup and whether the data favor SARCLISA + Pd or Pd alone. These data are also represented in the
HR (95% CI) column. 73/154 89/153 0.60 (0.44, 0.81)
Age, years
<65
65-74
≥75
26/54
32/68
15/32
41/70
29/54
19/29
0.66 (0.40, 1.07)
0.64 (0.39, 1.06)
0.48 (0.24, 0.95)
R-ISS stage at study entry
I
II
III
13/39
47/99
13/16
17/31
57/98
15/24
0.58 (0.28, 1.21)
0.59 (0.40, 0.87)
0.61 (0.28, 1.31)
Cytogenetic riska
Highb
Standard
14/24
50/103
22/36
48/78
0.66 (0.33, 1.28)
0.62 (0.42, 0.93)
Renal impairment
<60 mL/min/1.73 m2
≥60 mL/min/1.73 m2
30/55
36/87
29/49
55/96
0.50 (0.30, 0.85)
0.58 (0.38, 0.88)
Previous lines of therapy
2-3
>3
44/102
29/52
57/101
32/52
0.59 (0.40, 0.88)
0.59 (0.36, 0.98)
Refractory to a Pl
Yes
No
57/118
16/36
67/115
22/38
0.58 (0.41, 0.82)
0.67 (0.35, 1.28)
Refractory to lenalidomide
Yes
No
72/144
1/10
82/140
7/13
0.59 (0.43, 0.82)
0.18 (0.02, 1.49)
Refractory to lenalidomide and a Pl
Yes
No
56/111
17/43
62/107
27/46
0.58 (0.40, 0.84)
0.60 (0.33, 1.11)
Previous ASCT
Yes
No
40/83
33/71
55/90
34/63
0.60 (0.40, 0.90)
0.62 (0.38, 1.00)

aCytogenetic risk information was missing for 18% of patients in the SARCLISA + Pd arm and 26% of patients in the Pd arm.1

bOf the patients who had high-risk chromosomal abnormalities at study entry, del(17p), t(4;14), and t(14;16) were present in 12%, 8%, and 2% of patients, respectively.3

Study limitations
Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.

ASCT=autologous stem cell transplant; IMiD=immunomodulatory drug; Pd=pomalidomide and dexamethasone; PFS=progression-free survival; PI=proteasome inhibitor; R-ISS=Revised International Staging System.

PFS and rate of ≥VGPR with SARCLISA + Pd in patients with renal impairment*

PFS in patients with renal impairment4

A Kaplan-Meier curve compares the median progression-free survival (mPFS) of patients with renal impairment receiving
                                                    SARCLISA + Pd (mPFS 9.5 months) vs Pd alone (mPFS 3.7 months); HR=0.50 (95% CI: 0.30, 0.85).

≥VGPR in patients with renal impairment4

Two bar charts compare the VGPR and CR outcomes for both treatment arms. ≥VGPR: 33% with SARCLISA + Pd vs 4% with
                                                Pd alone; CR: 5.5% with SARCLISA + Pd vs 2% with Pd alone.

Study limitations
Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.

*eGFR <60 mL/min/1.73 m2.3
CR=complete response; eGFR=estimated glomerular filtration rate; mPFS=median progression-free survival; VGPR=very good partial response.

Reduction in the risk of disease progression in patients treated with SARCLISA + Pd vs Pd alone1

Study limitations
Prespecified subgroup analysis; subgroups were not powered to show differences between treatment arms.

Cytogenetics by central lab; cutoff 50% for del(17p), 30% for t(4;14) and t(14;16).1

Back to topTop